Get the Latest Investment Ideas Delivered Straight to Your Inbox. Subscribe

News Update


Pharma Developer to Release Topline Data from Phase 2b COVID-19 Trial by Month-End
News Update

Share on Stocktwits


Algernon Pharmaceuticals reported that it expects to release topline results from the Phase 2b portion of its multinational Phase 2b/3 COVID-19 Ifenprodil study sometime during the last week of March 2021.

Algernon Pharmaceuticals Inc. (AGN:CSE; AGNPF:OTCQB; AGW:FSE) announced in a news release that "it expects to report its topline results for the Phase 2b part of its Phase 2b/3 COVID-19 trial of Ifenprodil, in the last week of March 2021."

The firm advised that independent statisticians will be the only parties having access to the data from the study while it is being compiled and analyzed. The company noted that after it receives the summary report and trial results and has a chance to review them internally, it plans to release the information to the public.

Algernon Pharmaceuticals' CEO Christopher J. Moreau commented, "While there has been an impressive advancement in the area of vaccine development and deployment, there still remains an urgent need to identify a therapeutic for the treatment of the most seriously affected COVID-19 patients...We sincerely hope that the trial results will show that Ifenprodil is reducing both the severity and duration of a COVID-19 infection."

The firm stated that it currently is not making claims of any kind as to Ifenprodil's ability to contain, cure or eliminate SARS-CoV-2, which is frequently referred to as the coronavirus or COVID-19.

The name of the Phase 2b/3 COVID-19 human trial is "A Randomized Open Label Phase 2b/3 Study of the Safety and Efficacy of NP-120 (Ifenprodil) for the Treatment of Hospitalized Patients with Confirmed COVID-19 Disease."

Algernon explained that the Phase 2b part of the study that enrolled a total of 150 patients is complete and noted that should the Phase 2b data prove to be positive then it plans to quickly move forward directly into a Phase 3 trial. The company advised that the exact Phase 2b study results will dictate the size of the pool of patients needed in a Phase 3 trial to ensure statistical significance.

The company advised that patients enrolled in the Phase 2 part of the study were randomized and treated using an existing standard of care or standard of care plus Ifenprodil in either 60 mg or 120 mg doses spread across three equal daily doses for a period of two weeks.

Algernon indicated that "NP-120 (Ifenprodil) is a N-methyl-D-aspartate (NMDA) receptor antagonist specifically targeting the NMDA-type subunit 2B (Glu2NB) that prevents glutamate signaling." The company explained that NMDA receptors can be found on tissues such as lung cells, T-cells and neutrophils.

The firm noted that it "believes Ifenprodil can reduce the infiltration of neutrophils and T-cells into the lungs where they can release glutamate and cytokines respectively." The company added that the release of cytokines can contribute greatly to highly problematic cytokine storm reactions that can result in loss of lung function and even death ultimately in patients infected with COVID-19.


1) Stephen Hytha compiled this article for Streetwise Reports LLC and provides services to Streetwise Reports as an independent contractor. He or members of his household own securities of the following companies mentioned in the article: None. He or members of his household are paid by the following companies mentioned in this article: None.
2) The following companies mentioned in this article are billboard sponsors of Streetwise Reports: Algernon Pharmaceuticals. Click here for important disclosures about sponsor fees. As of the date of this article, an affiliate of Streetwise Reports has a consulting relationship with Algernon Pharmaceuticals. Please click here for more information.
3) Comments and opinions expressed are those of the specific experts and not of Streetwise Reports or its officers. The information provided above is for informational purposes only and is not a recommendation to buy or sell any security.
4) The article does not constitute investment advice. Each reader is encouraged to consult with his or her individual financial professional and any action a reader takes as a result of information presented here is his or her own responsibility. By opening this page, each reader accepts and agrees to Streetwise Reports' terms of use and full legal disclaimer. This article is not a solicitation for investment. Streetwise Reports does not render general or specific investment advice and the information on Streetwise Reports should not be considered a recommendation to buy or sell any security. Streetwise Reports does not endorse or recommend the business, products, services or securities of any company mentioned on Streetwise Reports.
5) From time to time, Streetwise Reports LLC and its directors, officers, employees or members of their families, as well as persons interviewed for articles and interviews on the site, may have a long or short position in securities mentioned. Directors, officers, employees or members of their immediate families are prohibited from making purchases and/or sales of those securities in the open market or otherwise from the time of the decision to publish an article until three business days after the publication of the article. The foregoing prohibition does not apply to articles that in substance only restate previously published company releases. As of the date of this article, officers and/or employees of Streetwise Reports LLC (including members of their household) own securities of Algernon Pharmaceuticals, a company mentioned in this article.
6) This article does not constitute medical advice. Officers, employees and contributors to Streetwise Reports are not licensed medical professionals. Readers should always contact their healthcare professionals for medical advice.

Want to read more about Biotechnology / Pharmaceuticals investment ideas?
Get Our Streetwise Reports Life Sciences Report Newsletter Free and be the first to know!

A valid email address is required to subscribe